Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction
New biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, ha...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/15/5404 |
| _version_ | 1797560940675203072 |
|---|---|
| author | Marco Quaglia Guido Merlotti Gabriele Guglielmetti Giuseppe Castellano Vincenzo Cantaluppi |
| author_facet | Marco Quaglia Guido Merlotti Gabriele Guglielmetti Giuseppe Castellano Vincenzo Cantaluppi |
| author_sort | Marco Quaglia |
| collection | DOAJ |
| description | New biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, have been proposed for post-transplant delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction (CAD). This review investigates old and new potential biomarkers for each of these clinical domains, seeking to underline their limits and strengths. OMICs technology has allowed identifying many candidate biomarkers, providing diagnostic and prognostic information at very early stages of pathological processes, such as AR. Donor-derived cell-free DNA (ddcfDNA) and extracellular vesicles (EVs) are further promising tools. Although most of these biomarkers still need to be validated in multiple independent cohorts and standardized, they are paving the way for substantial advances, such as the possibility of accurately predicting risk of DGF before graft is implanted, of making a “molecular” diagnosis of subclinical rejection even before histological lesions develop, or of dissecting etiology of CAD. Identification of “immunoquiescent” or even tolerant patients to guide minimization of immunosuppressive therapy is another area of active research. The parallel progress in imaging techniques, bioinformatics, and artificial intelligence (AI) is helping to fully exploit the wealth of information provided by biomarkers, leading to improved disease nosology of old entities such as transplant glomerulopathy. Prospective studies are needed to assess whether introduction of these new sets of biomarkers into clinical practice could actually reduce the need for renal biopsy, integrate traditional tools, and ultimately improve graft survival compared to current management. |
| first_indexed | 2024-03-10T18:07:05Z |
| format | Article |
| id | doaj.art-b7f70195f7284ee69f1317876462dec3 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T18:07:05Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b7f70195f7284ee69f1317876462dec32023-11-20T08:25:04ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-012115540410.3390/ijms21155404Recent Advances on Biomarkers of Early and Late Kidney Graft DysfunctionMarco Quaglia0Guido Merlotti1Gabriele Guglielmetti2Giuseppe Castellano3Vincenzo Cantaluppi4Nephrology and Kidney Transplantation Unit, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), Department of Translational Medicine, University of Piemonte Orientale (UPO), AOU Maggiore della Carità, via Gen. P. Solaroli, 17-28100 Novara, ItalyNephrology and Kidney Transplantation Unit, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), Department of Translational Medicine, University of Piemonte Orientale (UPO), AOU Maggiore della Carità, via Gen. P. Solaroli, 17-28100 Novara, ItalyNephrology and Kidney Transplantation Unit, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), Department of Translational Medicine, University of Piemonte Orientale (UPO), AOU Maggiore della Carità, via Gen. P. Solaroli, 17-28100 Novara, ItalyNephrology, Dialysis and Transplant Unit, Department of Medical and Surgical Sciences, University of Foggia, 71121 Foggia, ItalyNephrology and Kidney Transplantation Unit, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), Department of Translational Medicine, University of Piemonte Orientale (UPO), AOU Maggiore della Carità, via Gen. P. Solaroli, 17-28100 Novara, ItalyNew biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, have been proposed for post-transplant delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction (CAD). This review investigates old and new potential biomarkers for each of these clinical domains, seeking to underline their limits and strengths. OMICs technology has allowed identifying many candidate biomarkers, providing diagnostic and prognostic information at very early stages of pathological processes, such as AR. Donor-derived cell-free DNA (ddcfDNA) and extracellular vesicles (EVs) are further promising tools. Although most of these biomarkers still need to be validated in multiple independent cohorts and standardized, they are paving the way for substantial advances, such as the possibility of accurately predicting risk of DGF before graft is implanted, of making a “molecular” diagnosis of subclinical rejection even before histological lesions develop, or of dissecting etiology of CAD. Identification of “immunoquiescent” or even tolerant patients to guide minimization of immunosuppressive therapy is another area of active research. The parallel progress in imaging techniques, bioinformatics, and artificial intelligence (AI) is helping to fully exploit the wealth of information provided by biomarkers, leading to improved disease nosology of old entities such as transplant glomerulopathy. Prospective studies are needed to assess whether introduction of these new sets of biomarkers into clinical practice could actually reduce the need for renal biopsy, integrate traditional tools, and ultimately improve graft survival compared to current management.https://www.mdpi.com/1422-0067/21/15/5404renal transplantbiomarkersextracellular vesiclesacute rejectionchronic rejectionchronic allograft dysfunction |
| spellingShingle | Marco Quaglia Guido Merlotti Gabriele Guglielmetti Giuseppe Castellano Vincenzo Cantaluppi Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction International Journal of Molecular Sciences renal transplant biomarkers extracellular vesicles acute rejection chronic rejection chronic allograft dysfunction |
| title | Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction |
| title_full | Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction |
| title_fullStr | Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction |
| title_full_unstemmed | Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction |
| title_short | Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction |
| title_sort | recent advances on biomarkers of early and late kidney graft dysfunction |
| topic | renal transplant biomarkers extracellular vesicles acute rejection chronic rejection chronic allograft dysfunction |
| url | https://www.mdpi.com/1422-0067/21/15/5404 |
| work_keys_str_mv | AT marcoquaglia recentadvancesonbiomarkersofearlyandlatekidneygraftdysfunction AT guidomerlotti recentadvancesonbiomarkersofearlyandlatekidneygraftdysfunction AT gabrieleguglielmetti recentadvancesonbiomarkersofearlyandlatekidneygraftdysfunction AT giuseppecastellano recentadvancesonbiomarkersofearlyandlatekidneygraftdysfunction AT vincenzocantaluppi recentadvancesonbiomarkersofearlyandlatekidneygraftdysfunction |